MannKind Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MannKind Corp (MNKD)
MannKind Corp stock price live, this page displays NASDAQ MNKD stock exchange data. View the MNKD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MannKind Corp real time stock price chart below.
What Is the MannKind Corp Stock Price Today?
The MannKind Corp stock price today is 3.520.
What Is the Stock Symbol for MannKind Corp?
The stock symbol for MannKind Corp is "MNKD."
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MNKD quote. (ISIN: US56400P7069)
What Is the MannKind Corp Stock Price Today?
The MannKind Corp stock price today is 3.520.
What Is the Stock Symbol for MannKind Corp?
The stock symbol for MannKind Corp is "MNKD."
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MNKD quote. (ISIN: US56400P7069)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.400
3.680
52 wk Range
2.230
6.510
MNKD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.4003.680
52 wk Range
2.2306.510
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MNKD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.219
Upside
+105.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- MannKind Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Why is MannKind stock surging today?
- Investing.com
- MannKind Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- MannKind Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - MannKind Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - MannKind Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.219
(+105.08% Upside)
MannKind Corp SWOT Analysis
Inhaled Innovation | Explore MannKind's pioneering inhaled therapeutics, focusing on Tyvaso DPI and Afrezza, as the company navigates growth and challenges in specialized markets. |
Pipeline Potential | Delve into MannKind's promising pipeline, including NTM and IPF treatments, set to begin trials in June 2024, potentially reshaping the company's market position. |
Financial Trajectory | Learn about MannKind's robust 63% year-over-year revenue growth, driven by Tyvaso DPI, with 2024 revenue estimates increased to $266 million from $259.1 million. |
Market Outlook | Analyst price targets range from $5.00 to $6.50, reflecting optimism tempered by pipeline dependencies and interest expense concerns in a competitive landscape. |
MannKind Corp Earnings Call Summary for Q1/2026
- Q1 2026 revenue rose 15% YoY to $90M, driven by FUROSCIX addition from scPharmaceuticals acquisition; stock surged 18.88% to $3.40.
- Non-GAAP net loss of $0.02/share missed forecast of -$0.01/share; revenue of $90M fell short of $107.53M estimate by 16.12%.
- FUROSCIX generated $15.5M in new revenue; Afrezza sales grew 3% to $15.3M; royalty revenue increased 9% to $32.7M YoY.
- Company projects EPS of $0.01 for Q3 2026 and $0.03 for Q4 2026, with revenue targets of $121.34M and $129.05M respectively.
- CEO emphasizes strategic focus on pediatric Afrezza launch and FUROSCIX nephrology expansion despite integration challenges and competitive pressures.
Last Updated: 2026-05-06, 06:48 p/m
Read Full TranscriptEarnings
Latest Release
May 06, 2026
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
90.2M / 107.53M
Compare MNKD to Peers and Sector
Metrics to compare | MNKD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNKDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −45.5x | 4.9x | −0.5x | |
PEG Ratio | −2.34 | 0.12 | 0.00 | |
Price/Book | −18.4x | 3.7x | 2.6x | |
Price / LTM Sales | 3.0x | 4.0x | 3.2x | |
Upside (Analyst Target) | 110.7% | 238.8% | 47.8% | |
Fair Value Upside | Unlock | 37.5% | 5.9% | Unlock |
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the MannKind (MNKD) Stock Price Today?
The MannKind stock price today is 3.520 USD.
What Stock Exchange Does MannKind Trade On?
MannKind is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MannKind?
The stock symbol for MannKind is "MNKD."
What Is the MannKind Market Cap?
As of today, MannKind market cap is 1.090B USD.
What Is MannKind's Earnings Per Share (TTM)?
The MannKind EPS (TTM) is -0.087.
When Is the Next MannKind Earnings Date?
MannKind will release its next earnings report on Aug 12, 2026.
From a Technical Analysis Perspective, Is MNKD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has MannKind Stock Split?
MannKind has split 1 times.
How Many Employees Does MannKind Have?
MannKind has 592 employees.
What is the current trading status of MannKind (MNKD)?
As of May 09, 2026, MannKind (MNKD) is trading at a price of 3.520 USD, with a previous close of 3.550 USD. The stock has fluctuated within a day range of 3.400 USD to 3.680 USD, while its 52-week range spans from 2.230 USD to 6.510 USD.
What Is MannKind (MNKD) Price Target According to Analysts?
The average 12-month price target for MannKind is 7.219 USD, with a high estimate of 10 USD and a low estimate of 4.75 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +105.08% Upside potential.
What Is the MNKD Premarket Price?
MNKD's last pre-market stock price is 3.590 USD. The pre-market share volume is 85,390.000, and the stock has decreased by 0.040, or 1.130%.
What Is the MNKD After Hours Price?
MNKD's last after hours stock price is 3.597 USD, the stock has decreased by 0.077, or 2.190%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.